Dr Steve Pereira to Advise Abcodia on its Pancreatic Cancer Programmes
Abcodia, a company focussed on biomarkers for the early detection and screening of cancer,has appointed Dr Steve Pereira as a specialist advisor to support Abcodia's programmes for developing biomarkers for the early diagnosis and screening of pancreatic cancer.
Dr Pereira is a consultant gastroenterologist at several hospitals in London, a reader at University College London and his clinical and research interests centre on the causes, early diagnosis and treatment of liver and pancreatic cancer, as well as benign biliary and pancreatic diseases.
He is currently Chairman of the British Society of Gastroenterology's Pancreatic Section.
Biomarkers for pancreatic cancer were the first of Abcodia's research programmes and the early results of these collaborative projects are promising.
Pancreatic cancer is the fourth most common cause of cancer related mortality and the five year survival rate is less than 4%.
We believe that identifying biomarkers that can be used for the early detection or screening will bring about significant health benefits.
Dr Julie Barnes, Abcodia's CEO, said: "The clinical research expertise that Steve brings to Abcodia will be extremely valuable in guiding our research and commercialisation of pancreatic cancer screening biomarkers that are in development by Abcodia and our collaborators"
Dr Steve Pereira
added "I'm excited by the opportunities which Abcodia
offers for pancreatic cancer screening and in particular to increase the survival rate for pancreatic cancer which has not improved for over 30 years.
The work that Abcodia
is doing in this area is a critical part of being able to realise our hopes of saving more lives from this devastating illness."
*A digital image of Dr Pereira
is available on request.